Skip to content
← All treatment topics

TREATMENT READING

Gastrointestinal Stromal Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

56 sections
  1. Response to therapy
  2. Treatment Option Overview for GISTs
  3. Surgery
  4. Chemotherapy
  5. Tyrosine Kinase Inhibitor (TKI) Therapy
  6. Radiation Therapy
  7. Treatment of Resectable Primary GISTs
  8. Treatment Options for Resectable Primary GISTs
  9. Surgery
  10. Postoperative adjuvant TKI therapy
  11. Imatinib
  12. Treatment of Unresectable Primary GISTs
  13. Treatment Options for Unresectable Primary GISTs
  14. Neoadjuvant TKI therapy
  15. Imatinib
  16. Treatment of Metastatic or Recurrent GISTs
  17. Treatment Options for Metastatic or Recurrent GISTs
  18. Initial TKI therapy
  19. Imatinib
  20. Initial TKI therapy for PDGFRA D842V-variant GISTs
  21. Avapritinib
  22. TKI therapy for imatinib-resistant GISTs
  23. Sunitinib
  24. Regorafenib
  25. Additional TKI therapy options
  26. Ripretinib
  27. Nilotinib
  28. Sorafenib
  29. Pazopanib
  30. TKI therapy for KIT/PDGFRA wild-type GISTs
  31. Surgery
  32. Clinical trials
  33. Treatment of Resistant or Refractory GISTs
  34. Key References for Treatment of GISTs
  35. Preoperative Imatinib
  36. Postoperative Imatinib
  37. Advanced GIST Tyrosine Kinase Inhibitors
  38. Certain factors affect prognosis (chance of recovery) and treatment options.
  39. The results of diagnostic and staging tests are used to plan treatment.
  40. Treatment Option Overview
  41. Key Points
  42. There are different types of treatment for patients with gastrointestinal stromal tumors.
  43. Four types of standard treatment are used:
  44. Surgery
  45. Targeted therapy
  46. Watchful waiting
  47. Supportive care
  48. New types of treatment are being tested in clinical trials.
  49. Treatment for gastrointestinal stromal tumors may cause side effects.
  50. Patients may want to think about taking part in a clinical trial.
  51. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  52. Follow-up tests may be needed.
  53. Treatment of Resectable Gastrointestinal Stromal Tumors
  54. Treatment of Unresectable Gastrointestinal Stromal Tumors
  55. Treatment of Metastatic and Recurrent Gastrointestinal Stromal Tumors
  56. Treatment of Refractory Gastrointestinal Stromal Tumors

Health professional · General Information About Gastrointestinal Stromal Tumors (GISTs) / Follow-Up

Response to therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

CT, fluorine F 18-fludeoxyglucose (18F-FDG) PET, and MRI are used to monitor the effects of systemic therapy in patients with unresectable, metastatic, or recurrent disease.[34]

Sources: 34

A baseline PET should be performed before tyrosine kinase inhibitor (TKI) therapy in patients who will be monitored for response with 18F-FDG PET. PET imaging may detect the activity of imatinib in GISTs much earlier than CT imaging, with decreased tumor avidity detected as soon as 24 hours after the first dose. Thus, PET may be a useful diagnostic modality for the very early assessment of response to imatinib therapy and for detecting resistance to TKIs.[12]

Sources: 12

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment Option Overview for GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

The management of patients with gastrointestinal stromal tumors (GISTs) is a multidisciplinary effort involving close collaboration between pathologists, medical oncologists, surgeons, and imaging experts.[1]

Sources: 1

Health professional · Treatment Option Overview for GISTs

Surgery

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Surgical resection is the primary treatment modality for the following types of patients:[2][Level of evidence C2]

Sources: 2 · Level of evidence C2

Those with primary GISTs who do not have evidence of metastasis.

Those with tumors that are technically resectable (e.g., GISTs that do not require a formal gastrectomy, pancreatectomy, or other major organ resection) if the risks of morbidity are acceptable.

Endoscopic surveillance is an option for patients with tumors measuring 2 cm or smaller with a mitotic index of 5 or less per 50 high-power fields. The low rates of progression and metastasis in these tumors make endoscopic surveillance viable in place of surgical resection.[3]

Sources: 3

The goal of surgery is complete gross resection with an intact pseudocapsule and negative microscopic margins.[4] Because GISTs are generally encapsulated and relatively less infiltrative than other malignancies, wide excision is not necessary. Lymphadenectomy is typically unnecessary, given that lymph node metastasis is rare with GISTs. However, lymphadenectomy should be considered in patients with SDH-deficient GISTs and pathologically enlarged lymph nodes.

Sources: 4

If anatomically feasible, laparoscopic surgery is increasingly performed instead of laparotomy. Reports demonstrate lower rates of recurrence, shorter hospital stays, and lower morbidity.[5-8]

Sources: 5 · 8

Neoadjuvant imatinib therapy can be given to patients with large tumors or difficult-to-access GISTs that are considered marginally resectable. Significant tumor shrinkage is often seen with targeted therapy, so this approach can potentially avoid major organ resection, or enable organ-sparing surgery. Genetic sequencing may be considered to identify sensitive or resistant variants prior to neoadjuvant imatinib therapy.

For patients with oligometastatic recurrences (e.g., isolated intra-abdominal implants or solitary liver lesions), surgical resection may be used in conjunction with tyrosine kinase inhibitors (TKIs).[9,10][Level of evidence C1] This should only be considered after multidisciplinary consultation.

Sources: 9 · 10 · Level of evidence C1

Health professional · Treatment Option Overview for GISTs

Chemotherapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

There is universal agreement that standard chemotherapy has no role in the primary therapy of GISTs.[4,11,12]

Sources: 4 · 11 · 12

Before the advent of molecularly targeted therapy with TKIs, efforts to treat GISTs with conventional cytotoxic chemotherapy were essentially futile.[1] The extreme resistance of GISTs to chemotherapy may be partly caused by the increased expression of P-glycoprotein, the product of the MDR-1 gene, and MRP1, which are cellular efflux pumps that may prevent chemotherapeutic agents from reaching therapeutic intracellular concentrations in GIST cells.[1,13]

Sources: 1 · 1 · 13

Health professional · Treatment Option Overview for GISTs

Tyrosine Kinase Inhibitor (TKI) Therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

TKIs work by inhibiting aberrantly functioning KIT or PDGFRA receptor tyrosine kinases and inducing rapid reduction in tumor growth. TKI therapy is indicated for patients with unresectable, borderline resectable, metastatic, or recurrent GISTs. It is also indicated as adjuvant therapy for patients with GISTs at high risk of recurrence.

The TKI imatinib mesylate is used as first-line therapy for most patients with KIT- and PDGFRA-variant GISTs.[14] For patients with GISTs characterized by a PDGFRA D842V variant, avapritinib is used as first-line therapy, given the high clinical benefit and imatinib-resistance in this subtype.[15] Other TKI agents approved for subsequent lines of therapy in patients with KIT/PDGFRA-variant GISTs include sunitinib, regorafenib, and ripretinib. Additional TKI agents that are occasionally given include nilotinib, sorafenib, and pazopanib.

Sources: 14 · 15

Imatinib is not typically given to patients with KIT/PDGFRA wild-type GISTs (i.e., SDH-deficient or neurofibromatosis type 1 [NF1]-related GISTs) because of high rates of resistance. Other TKIs (i.e., sunitinib or regorafenib) may have some activity, but most patients are recommended to consider enrolling in clinical trials, if eligible.

For more information on the efficacy, safety, and management of toxicity of imatinib, or additional agents in the setting of imatinib resistance or intolerance, see the sections on Treatment of Resectable Primary GISTs, Treatment of Unresectable Primary GISTs, and Treatment of Metastatic or Recurrent GISTs.

Sources: Treatment of Resectable Primary GISTs · Treatment of Unresectable Primary GISTs · Treatment of Metastatic or Recurrent GISTs

Health professional · Treatment Option Overview for GISTs

Radiation Therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Radiation therapy rarely has a role in the management of patients with GISTs. It may occasionally be used for palliation of painful metastases or for patients with unresectable bleeding tumors.[1]

Sources: 1

Health professional

Treatment of Resectable Primary GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Resectable Primary GISTs

Treatment Options for Resectable Primary GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Treatment options for resectable primary gastrointestinal stromal tumors (GISTs) include:

Surgery.

Sources: Surgery.

Postoperative adjuvant tyrosine kinase inhibitor (TKI) therapy.

Sources: Postoperative adjuvant tyrosine kinase inhibitor (TKI) therapy.

Postoperative adjuvant tyrosine kinase inhibitor (TKI) therapy.

Imatinib.

Sources: Imatinib

Health professional · Treatment of Resectable Primary GISTs / Treatment Options for Resectable Primary GISTs

Surgery

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

All GISTs measuring 2 cm or larger are typically surgically resected. The management of incidentally encountered GISTs measuring smaller than 2 cm remains controversial. There is no evidence for re-excision in patients with a complete resection of all macroscopic disease but microscopically positive margins. Watchful waiting and adjuvant imatinib therapy may be appropriate for these patients.[1,2]

Sources: 1 · 2

In general, gastric GISTs may be removed by laparoscopic wedge resection, when technically feasible. GISTs rarely involve the locoregional lymph nodes. Thus, extensive lymph node dissection is not indicated unless there is clinically apparent nodal involvement. These tumors may have fragile pseudocapsules, so care must be taken to avoid rupturing the pseudocapsule during surgery, which could result in peritoneal dissemination.

Health professional · Treatment of Resectable Primary GISTs / Treatment Options for Resectable Primary GISTs

Postoperative adjuvant TKI therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Resectable Primary GISTs / Treatment Options for Resectable Primary GISTs / Postoperative adjuvant TKI therapy

Imatinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Results from three phase III studies support the use of postoperative adjuvant imatinib for patients with completely resected localized GISTs who have a high risk of recurrence based on tumor size, tumor location, mitotic index, and presence of tumor rupture.[3-10]

Sources: 3 · 10

Evidence (phase III studies of postoperative imatinib):

ACOSOG Z9001 (NCT00041197) was a phase III, double-blind, placebo-controlled trial of 713 patients with fully resected KIT-variant GISTs measuring at least 3 cm. Patients were randomly assigned to receive either imatinib 400 mg daily (n = 359) or placebo (n = 354) for 1 year after surgical resection.[4]

Sources: ACOSOG Z9001 · 4

ACOSOG Z9001 (NCT00041197) was a phase III, double-blind, placebo-controlled trial of 713 patients with fully resected KIT-variant GISTs measuring at least 3 cm. Patients were randomly assigned to receive either imatinib 400 mg daily (n = 359) or placebo (n = 354) for 1 year after surgical resection.[4]

After a median follow-up of 19.7 months, disease recurrence or death occurred in 30 patients (8.4%) in the imatinib arm and 70 patients (19.8%) in the placebo arm.

The 1-year recurrence-free survival (RFS) rate was 98% in patients who received imatinib (95% confidence interval [CI], 96%–100%) and 83% (95% CI, 78%–88%) in patients who received placebo (hazard ratio [HR], 0.35; 95% CI, 0.22–0.53; P < .0001).[4][Level of evidence B1] No difference was noted in overall survival (OS) (HR, 0.66; 95% CI, 0.22–2.03; P = .4714).

Sources: 4 · Level of evidence B1

Dose-reduction or interruption because of adverse events occurred in 14.5% of patients in the imatinib arm and 2.8% of patients in the placebo arm. Grade 3 or 4 events occurred in 30.9% of patients in the imatinib arm and 18.3% of patients in the placebo arm.

EORTC-62024 (NCT00103168) was a phase III open-label trial of 908 patients with fully resected (R0 or R1 margin) KIT-variant GISTs at intermediate or high risk of recurrence. Patients were randomly assigned to receive either imatinib 400 mg daily (n = 454) or observation (n = 454) for 2 years.[10]

Sources: EORTC-62024 · 10

EORTC-62024 (NCT00103168) was a phase III open-label trial of 908 patients with fully resected (R0 or R1 margin) KIT-variant GISTs at intermediate or high risk of recurrence. Patients were randomly assigned to receive either imatinib 400 mg daily (n = 454) or observation (n = 454) for 2 years.[10]

At a median follow-up of 4.7 years, RFS rates were improved for patients who received imatinib compared with patients who underwent observation at 3 years (84% vs. 66%) and 5 years (69% vs. 63%) (log-rank P < .001).[10][Level of evidence B1] The 5-year OS rate did not differ between the imatinib and observation arms (91.8% vs. 92.7%).

Sources: 10 · Level of evidence B1

The 5-year imatinib failure-free survival rate (day of randomization to the start of a new systemic treatment or death) was 87% in the imatinib arm and 84% in the observation arm (HR, 0.79; 98.5% CI, 0.50–1.25; P = .21).[10][Level of evidence B1]

Sources: 10 · Level of evidence B1

A final analysis at a median follow-up of 9.1 years showed RFS rates of 70% and 63% at 5 and 10 years, respectively, for patients in the imatinib arm, and rates of 63% and 61% at 5 and 10 years, respectively, for patients in the observation arm (HR, 0.71; 95% CI, 0.57–0.89; P = .002). There was no difference in OS between patients who received imatinib and patients who underwent observation (93% vs. 92% at 5 years, 80% vs. 78% at 10 years; HR, 0.88; 95% CI, 0.65–1.21; P = .43).[9][Levels of evidence B1 and A1]

Sources: 9 · B1 · A1

SSG XVIII (NCT00116935) was a phase III open-label trial of 400 patients with fully resected, high-risk GISTs. Patients were randomly assigned to receive imatinib 400 mg daily for either 1 year (n = 200) or 3 years (n = 200) after resection.[5]

Sources: SSG XVIII · 5

SSG XVIII (NCT00116935) was a phase III open-label trial of 400 patients with fully resected, high-risk GISTs. Patients were randomly assigned to receive imatinib 400 mg daily for either 1 year (n = 200) or 3 years (n = 200) after resection.[5]

After a median follow-up of 54 months, the RFS rate was 65.6% in the 3-year arm and 47.9% in the 1-year arm (HR, 0.46; 95% CI, 0.32–0.65; P < .001).[5][Level of evidence B1]

Sources: 5 · Level of evidence B1

The 5-year OS rate was 92% in the 3-year arm and 81.7% in the 1-year arm (HR, 0.45; 95% CI, 0.22–0.89; P = .02).[5]

Sources: 5

Although generally well-tolerated in both groups, grade 3 or 4 events occurred in 32.8% of patients in 3-year arm and 20.1% of patients in the 1-year arm. Treatment discontinuation occurred in 25.8% of patients in 3-year arm and 12.6% of patients in the 1-year arm.

A post-hoc exploratory analysis suggested that patients with KIT exon 11–variant GISTs derived the most benefit from a longer duration of imatinib (5-year RFS, 71.0% vs. 41.3%; P < .001).[6]

Sources: 6

The recommended length of adjuvant treatment remains unknown. However, based on the SSG XVIII study results, at least 3 years of therapy is generally used in practice. It is important to note that evidence suggests that, instead of being cytotoxic, imatinib may suppress GIST growth. Therefore, recurrence may be delayed by the suppression of undetectable metastatic disease.[5,11-13] For example, the rate of recurrence increased within 6 to 12 months of discontinuing adjuvant imatinib in both the 1-year and 3-year arms in the SSG XVIII trial.[5] This concept has led to higher-risk patients being given imatinib indefinitely, although there is no direct trial evidence to support that.

Sources: 5 · 11 · 13 · 5

Most patients initiate imatinib therapy at a dosage of 400 mg per day. Molecular genotyping of patients with GISTs is recommended as it can impact the use of adjuvant imatinib, as well as the optimal dose. Patients whose tumor harbors a KIT exon 9 variant may benefit from higher-dose imatinib (800 mg per day) based on data in the metastatic setting.[14] Patients with KIT/PDGFRA wild-type GISTs (i.e., SDH-deficient and neurofibromatosis type 1 [NF1]-related GISTs) or PDGFRA D842V-variant GISTs are unlikely to benefit from adjuvant imatinib therapy.[5]

Sources: 14 · 5

Although not fully conclusive, there is some phase II evidence to support continuing adjuvant imatinib therapy for 5 years or more.

Evidence (phase II studies of postoperative imatinib):

PERSIST-5 (NCT00867113) was a single-arm phase II trial of 91 patients with fully resected, high-risk GISTs. Patients received imatinib (400 mg daily) for up to 5 years.[15][Level of evidence C1]

Sources: PERSIST-5 · 15 · Level of evidence C1

PERSIST-5 (NCT00867113) was a single-arm phase II trial of 91 patients with fully resected, high-risk GISTs. Patients received imatinib (400 mg daily) for up to 5 years.[15][Level of evidence C1]

The median treatment duration was 55.1 months, but with a large range (0.5–60.6 months). Only 46 patients (51%) completed all 5 years of therapy. Thus, 49% of patients stopped treatment early because of patient choice (21%), adverse events (16%), or other reasons (12%).

At a median follow-up of 19.6 months, the estimated 5-year RFS rate was 90% (95% CI, 80%–95%). The OS rate was 95% (95% CI, 86%–99%). Seven patients (7.6%) had a recurrence, 6 of which occurred after treatment discontinuation.

A small, single-institution, retrospective analysis included 234 patients with R0-resected GISTs at moderate to high risk of recurrence. The study evaluated the effect of differing durations of postoperative imatinib on 5-year RFS and OS rates.[13][Level of evidence C1]

Sources: 13 · Level of evidence C1

A small, single-institution, retrospective analysis included 234 patients with R0-resected GISTs at moderate to high risk of recurrence. The study evaluated the effect of differing durations of postoperative imatinib on 5-year RFS and OS rates.[13][Level of evidence C1]

At a median follow-up of 54 months, the 5-year RFS rate across all groups was 76.2%. The OS rate across all groups was 83.4%.

In high-risk patients, longer durations of imatinib therapy were associated with higher RFS rates (36.5% in the 1-year group, 68.7% in the 1–3-years group, 71.2% in the 3–5-years group, and 90.8% in the >5-years group; P < .001). Longer imatinib therapy duration was also associated with higher OS rates (36.7% in the 1-year group, 76.6% in the 1–3-years group, 84.0% in the 3–5-years group, and 97.4% in the >5-years group; P < .001).

Health professional

Treatment of Unresectable Primary GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Unresectable Primary GISTs

Treatment Options for Unresectable Primary GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Treatment options for unresectable primary gastrointestinal stromal tumors (GISTs) include:

Neoadjuvant tyrosine kinase inhibitor (TKI) therapy.

Sources: Neoadjuvant tyrosine kinase inhibitor (TKI) therapy.

Neoadjuvant tyrosine kinase inhibitor (TKI) therapy.

Imatinib.

Sources: Imatinib

Health professional · Treatment of Unresectable Primary GISTs / Treatment Options for Unresectable Primary GISTs

Neoadjuvant TKI therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Unresectable Primary GISTs / Treatment Options for Unresectable Primary GISTs / Neoadjuvant TKI therapy

Imatinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Neoadjuvant imatinib may be used for patients with very large primary GISTs or poorly positioned small GISTs (considered unresectable without the risk of significant morbidity or functional deficit, such as needing a formal gastrectomy, pancreatectomy, or other major organ resection) until surgical therapy is feasible, which can take as long as 6 to 12 months.[1,2] Neoadjuvant imatinib therapy in patients with GISTs is supported by the early results of two phase II studies in the United States [3] and Asia [4], as well as several case series and small retrospective reports.[2,5-10] Neoadjuvant imatinib may be particularly beneficial in rectal GISTs, given the large bulky nature of the disease and the extensive surgery required for complete resection.[11,12]

Sources: 1 · 2 · 3 · 4 · 2 · 5 · 10 · 11 · 12

Evidence (phase II studies of neoadjuvant imatinib):

RTOG-0132/ACRIN-6665 (NCT00028002) was a phase II single-arm study of 52 patients with primary GISTs (n = 30) or operable metastatic GISTs (n = 22). Patients received preoperative imatinib (600 mg daily) for 8 to 12 weeks followed by postoperative imatinib for at least 2 years.[3][Level of evidence C3]

Sources: RTOG-0132/ACRIN-6665 · 3 · Level of evidence C3

RTOG-0132/ACRIN-6665 (NCT00028002) was a phase II single-arm study of 52 patients with primary GISTs (n = 30) or operable metastatic GISTs (n = 22). Patients received preoperative imatinib (600 mg daily) for 8 to 12 weeks followed by postoperative imatinib for at least 2 years.[3][Level of evidence C3]

Among patients with primary GISTs, 83% had stable disease and 7% had a partial response (7%). Among patients with metastatic GISTs, 91% had stable disease, 4.5% had a partial response, and 4.5% had disease progression.

At a median follow-up of 36 months, the 2-year PFS rate was 83% in patients with primary GISTs and 77% in patients with metastatic GISTs. The OS rate was 93% in patients with primary GISTs and 91% in patients with metastatic GISTs.

Seventy-seven percent of patients with primary GISTs and 58% of patients with metastatic GISTs went on to have R0 resections. Five patients (10%) had unresectable disease.

Imatinib was generally well tolerated, although 35% of patients had grade 3 to 5 adverse events. The median preoperative duration of imatinib was 65 days, and the median time of imatinib discontinuation before surgery was 2 days.

A phase II single-arm study conducted in Asia included 53 evaluable patients with gastric GISTs larger than 10 cm. Patients received preoperative imatinib (400 mg daily) for 6 to 9 months, followed by at least 1 year of postoperative imatinib.[4][Level of evidence C3]

Sources: 4 · Level of evidence C3

A phase II single-arm study conducted in Asia included 53 evaluable patients with gastric GISTs larger than 10 cm. Patients received preoperative imatinib (400 mg daily) for 6 to 9 months, followed by at least 1 year of postoperative imatinib.[4][Level of evidence C3]

Forty-six patients (87%) received at least 6 months of preoperative imatinib and 50 patients ultimately underwent gastrectomy. The median duration of preoperative imatinib was 26 weeks. The most common grade 3 to 4 adverse events were neutropenia and rash.

The objective response rate was 62%, and the maximal reduction occurred most commonly at 24 weeks (63% of patients). The R0 resection rate was 91% overall, and at least one-half of the stomach was preserved in 79% of patients.

At a median follow-up of 32 months, the 2-year PFS rate was 89%, and the OS rate was 98%.

If a preoperative TKI is planned, a biopsy to confirm the diagnosis and, potentially, molecular profiling should be considered. Mutational analysis may help to exclude nonsensitive variants before starting imatinib cytoreduction therapy. Biopsy and molecular profiling may also determine whether a tumor harbors a KIT exon 9 variant, which may require an increase in initial imatinib dosing.[1,13] Neoadjuvant imatinib is not used for patients with GISTs harboring a PDGFRA D842V variant. Some guidelines, such as those from the European Society of Medical Oncology, recommend considering neoadjuvant avapritinib.[14] However, avapritinib has not been tested or validated in the neoadjuvant setting. In addition, patients with KIT/PDGFRA wild-type GISTs (i.e., SDH-deficient or neurofibromatosis type 1 [NF1]-related GISTs) would not benefit from neoadjuvant therapy and should proceed directly to surgery, if feasible.

Sources: 1 · 13 · 14

If indicated, neoadjuvant imatinib is initiated at 400 mg per day in most patients. Patients with KIT exon 9–variant GISTs may be offered a higher dose (800 mg per day) based on data from the advanced setting.[15] Follow-up imaging, with either computed tomography (CT) or positron emission tomography (PET)-CT, is performed at close intervals. PET-CT can be particularly helpful in assessing initial early response if baseline molecular profiling was not done before neoadjuvant therapy.[16] The optimal duration of neoadjuvant treatment is unknown and should be individualized based on multidisciplinary discussion. Neoadjuvant TKI therapy precludes the ability to risk stratify after surgical resection. Therefore, patients should continue imatinib after surgery for at least 3 total years.

Sources: 15 · 16

Health professional

Treatment of Metastatic or Recurrent GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent GISTs

Treatment Options for Metastatic or Recurrent GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Treatment options for metastatic or recurrent gastrointestinal stromal tumors (GISTs) include:

Initial tyrosine kinase inhibitor (TKI) therapy.

Sources: Initial tyrosine kinase inhibitor (TKI) therapy

Initial tyrosine kinase inhibitor (TKI) therapy.

Imatinib.

Sources: Imatinib

Initial TKI therapy for PDGFRA D842-variant GISTs.

Sources: Initial TKI therapy for PDGFRA D842-variant GISTs

Initial TKI therapy for PDGFRA D842-variant GISTs.

Avapritinib.

Sources: Avapritinib

TKI therapy for imatinib-resistant GISTs.

Sources: TKI therapy for imatinib-resistant GISTs

TKI therapy for imatinib-resistant GISTs.

Sunitinib.

Sources: Sunitinib

Regorafenib.

Sources: Regorafenib

Additional TKI therapy options.

Sources: Additional TKI therapy options

Additional TKI therapy options.

Ripretinib.

Sources: Ripretinib

Nilotinib.

Sources: Nilotinib

Sorafenib.

Sources: Sorafenib

Pazopanib.

Sources: Pazopanib

TKI therapy for KIT/PDGFRA wild-type GISTs.

Sources: TKI therapy for KIT/PDGFRA wild-type GISTs

Surgery.

Sources: Surgery

Clinical trials.

Sources: Clinical trials

The primary treatment of patients with metastatic or recurrent GISTs involves medical therapy with a TKI. In select cases, surgical therapy may be added. Patients with metastatic or recurrent tumors that do not respond to these measures may be candidates for clinical trials.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

Initial TKI therapy

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Initial TKI therapy

Imatinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Therapy with imatinib is the standard first-line treatment for most patients with metastatic or recurrent disease. The initial dose is 400 mg daily, except for patients with tumors containing KIT exon 9 variants, who may receive 800 mg daily.[1] The only exception is for patients with GISTs characterized by the PDGFRA D842V variant. In this subtype, avapritinib is used as first-line therapy given high clinical benefit and imatinib resistance.[2] Most patients can initiate imatinib empirically while awaiting confirmation of their tumor’s molecular profile. That profile may necessitate an imatinib dosing change (i.e., KIT exon 9), a change to avapritinib (i.e., PDGFRA D842V variant), or indicate likelihood for TKI resistance (i.e., SDH-deficient or neurofibromatosis type 1 [NF1]-related GISTs).

Sources: 1 · 2

All patients receiving TKI therapy are closely monitored for tumor response and side effects, which may require dose reductions, interruptions, or cessation of TKI therapy in cases of persistent, excessive toxicity. In addition, dose modification of the TKI or substitution with medications that do not affect cytochrome P450 isoenzyme 3A4 (CYP450 3A4) levels may be necessary for patients taking drugs that affect CYP450 3A4 levels.[3]

Sources: 3

Response is evaluated with computed tomography (CT), magnetic resonance imaging (MRI), or fluorine F 18-fludeoxyglucose positron emission tomography (18F-FDG PET).[3-7] Treatment is usually continued indefinitely in the absence of disease progression or unacceptable toxicity, with a median time to progression of 24 to 40 months and median survival approaching 45 to 60 months.[3,8-14] A cohort of patients from early imatinib trials have continued on therapy with long-term survival. In a multivariable analysis, age younger than 60 years, performance status 0, smaller size of the largest lesion, and exon 11 KIT variant were significant prognostic factors for the probability of surviving beyond 10 years.[10] A similar finding for exon 11 was seen in a phase II study.[9]

Sources: 3 · 7 · 3 · 8 · 14 · 10 · 9

Evidence (imatinib therapy):

A phase III trial included 746 patients with advanced unresectable or metastatic GISTs. Patients were randomly assigned to receive either higher-dose treatment with 800 mg imatinib daily or 400 mg imatinib daily as primary systemic therapy.

A phase III trial included 746 patients with advanced unresectable or metastatic GISTs. Patients were randomly assigned to receive either higher-dose treatment with 800 mg imatinib daily or 400 mg imatinib daily as primary systemic therapy.

No statistically significant differences in objective response rates, progression-free survival (PFS), or overall survival (OS) were observed between patients who received the 800 mg dose and patients who received the 400 mg dose.[15][Levels of evidence A1; B1; and B3]

Sources: 15 · A1 · B1 · B3

Among patients who progressed at 400 mg daily and crossed over to 800 mg daily, approximately one-third were able to achieve an objective response or disease stabilization.

Similar findings were seen in a European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) study of 946 patients with GISTs who were randomly assigned to receive 400 mg or 800 mg of imatinib, with crossover permitted at progression.[16]

Sources: 16

It is now recognized that specific kinase variants in KIT and PDGFRA impact sensitivity/response to imatinib (e.g., exon 11 is imatinib sensitive and exon 9 is imatinib resistant).[17-21] In addition, meta-analyses of both trials mentioned above have demonstrated that patients with KIT exon 9 variants have significant benefit with higher-dose imatinib.[22]

Sources: 17 · 21 · 22

In the event of tumor progression in patients without KIT exon 9 variants on lower dose imatinib (i.e., 400 mg daily), the imatinib dosage may be increased to 800 mg daily (in split doses). Alternatively, in the management of imatinib resistance, the patient may be switched directly to sunitinib.[23]

Sources: 23

The most common toxicities associated with imatinib therapy, all of which may improve with prolonged treatment, include:[6,11,24-26]

Sources: 6 · 11 · 24 · 26

Fluid retention (especially periorbital edema or peripheral edema; occasionally pleural effusion or ascites).

Diarrhea.

Nausea (may be diminished if taken with food).

Fatigue.

Muscle cramps.

Abdominal pain.

Rash.

Mild (macrocytic) anemia.

Hypophosphatemia.

There are rare reports of heart failure related to imatinib use,[27] primarily in patients with preexisting heart disease. No excess cardiac toxicity was noted in either of the phase III trials of imatinib mentioned above for patients with advanced GISTs.[15,16] However, it is best to inform patients of this risk before starting imatinib and monitor clinically for signs of heart failure or left ventricular dysfunction.

Sources: 27 · 15 · 16

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

Initial TKI therapy for PDGFRA D842V-variant GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Initial TKI therapy for PDGFRA D842V-variant GISTs

Avapritinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Patients with GISTs that harbor a PDGFRA exon 18 D842V variant should initially be given avapritinib. However, for patients whose GISTs are asymptomatic or indolent, a period of observation is reasonable to avoid treatment toxicities.

Evidence (avapritinib in patients with a PDGFRA D842V variant):

NAVIGATOR (NCT02508532) was a phase I, single-arm, open-label trial of 56 patients with a PDGFRA D842V variant. Patients received avapritinib at a daily dose of either 300 mg or 400 mg.[2][Level of evidence C3]

Sources: NAVIGATOR · 2 · Level of evidence C3

NAVIGATOR (NCT02508532) was a phase I, single-arm, open-label trial of 56 patients with a PDGFRA D842V variant. Patients received avapritinib at a daily dose of either 300 mg or 400 mg.[2][Level of evidence C3]

An overall response was seen in 49 of 56 patients (88%) (95% confidence interval [CI], 76%–95%), with five patients (9%) achieving a complete response.

The 1-year PFS rate was 81% (95% CI, 67%–94%) and the 1-year duration of response was 70% (95% CI, 54%–87%).

At median follow-up of 15.9 months, the estimated 1-year OS rate was 91%, and the estimated 2-year OS rate was 81%.

The high overall response rate results of the NAVIGATOR trial led the U.S. Food and Drug Administration (FDA) to approve avapritinib for patients with GISTs with a PDGFRA exon 18 variant, including D842V variants.

Evidence (avapritinib in patients who did not respond to imatinib and at least one additional TKI):

VOYAGER (NCT03465722) was a phase III open-label trial of 476 patients with advanced GISTs that did not respond to imatinib and at least one additional TKI. Patients were randomly assigned to receive either avapritinib 300 mg daily (n = 240) or regorafenib 160 mg daily (3-weeks-on/1-week-off regimen) (n = 236), with crossover allowed from regorafenib to avapritinib.[28]

Sources: VOYAGER · 28

VOYAGER (NCT03465722) was a phase III open-label trial of 476 patients with advanced GISTs that did not respond to imatinib and at least one additional TKI. Patients were randomly assigned to receive either avapritinib 300 mg daily (n = 240) or regorafenib 160 mg daily (3-weeks-on/1-week-off regimen) (n = 236), with crossover allowed from regorafenib to avapritinib.[28]

The median PFS was 4.2 months in the avapritinib arm and 5.6 months in the regorafenib arm (hazard ratio [HR], 1.25; 95% CI, 0.99–1.57; P = .055). Among patients without a PDGFRA D842V variant, the median PFS was 3.9 months in the avapritinib arm and 5.6 months in the regorafenib arm (HR, 1.34; 95% CI, 1.06–1.69; P = .012).[28][Level of evidence B1]

Sources: 28 · Level of evidence B1

OS data were immature at the time of the report with no interval differences noted between the study arms.

Overall and grade 3 or higher treatment-related adverse events did not differ between groups. However, cognitive effects occurred more often in patients who received avapritinib (25.9%) than in patients who received regorafenib (3.8%).

Because avapritinib did not improve PFS or OS compared with regorafenib in the treated population, it is not indicated until patients have failed multiple previous TKI therapies (outside of its specific variant indication above).

If indicated, avapritinib is given at 300 mg daily. Avapritinib is teratogenic, and thus, warrants effective contraception during and up to 6 weeks after the final dose.[29] The 300 mg dose was generally well-tolerated in the phase I NAVIGATOR study, with grade 3 to 4 toxicities including anemia, hyperbilirubinemia, fatigue, abdominal pain, diarrhea, peripheral edema, pleural effusion, and cognitive impairment.[2]

Sources: 29 · 2

Cognitive effects must be closely monitored, with treatment changes (reductions, modifications, discontinuation) made promptly. Based on a post-hoc analysis of patients receiving 300 mg daily, grade 1 to 2 cognitive effects were seen in 37% of patients and 52% of patients older than 65 years. These effects included cognitive impairment, mood changes, sleep disorder, dizziness, hallucinations, and intracranial hemorrhage. These cognitive effects generally improved once treatment changes were made.[29]

Sources: 29

Of note, for patients with GISTs who do not harbor a PDGFRA D842V variant, avapritinib should not be used until imatinib and at least two additional agents (sunitinib and regorafenib) are tried. The open-label phase III VOYAGER trial demonstrated that regorafenib improved PFS more than avapritinib in patients without a PDGFRA D842V variant.[28]

Sources: 28

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

TKI therapy for imatinib-resistant GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / TKI therapy for imatinib-resistant GISTs

Sunitinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

In the case of tumor progression (or intolerance to imatinib), data support second-line therapy with either imatinib dose escalation to 800 mg per day (as described above) or sunitinib.[16,21] Sunitinib is given at a dose of 50 mg daily in a 4-weeks-on/2-weeks-off regimen or a daily dose of 37.5 mg.[30] As with imatinib, the response to sunitinib is evaluated with CT, MRI, or 18F-FDG PET, and treatment is usually continued indefinitely in the absence of disease progression or unacceptable toxicity.[3,4,30-36]

Sources: 16 · 21 · 30 · 3 · 4 · 30 · 36

Evidence (sunitinib):

An international phase III trial of 312 patients with imatinib-resistant GISTs randomly assigned patients to receive sunitinib or placebo.[30]

Sources: 30

An international phase III trial of 312 patients with imatinib-resistant GISTs randomly assigned patients to receive sunitinib or placebo.[30]

On the basis of radiological assessment, the median time to tumor progression was more than four times as long with sunitinib (27.3 weeks; 95% CI, 16.0–32.1) than with placebo treatment (6.4 weeks; 95% CI, 4.4–10.0) (HR, 0.33; 95% CI, 0.23–0.47; P < .0001).[30][Level of evidence A1]

Sources: 30 · Level of evidence A1

OS was similarly better for sunitinib-treated patients (HRdeath, 0.49; 95% CI, 0.29–0.83).[30][Level of evidence A1]

Sources: 30 · Level of evidence A1

The response to sunitinib is also influenced by the molecular profile of the GIST. Based on a phase I/II study of 97 patients, the highest clinical benefit rate, PFS benefit, and OS benefit were seen in patients with KIT exon 9 variants, compared with patients with KIT/PDGFRA wild-type or KIT exon 11 variants.[33]

Sources: 33

Common side effects associated with sunitinib include:[30,37]

Sources: 30 · 37

Fatigue.

Nausea and vomiting.

Anemia.

Neutropenia.

Diarrhea.

Abdominal pain.

Mucositis.

Anorexia.

Skin or hair discoloration.

Proteinuria.

Hypothyroidism (thyroid function monitoring is generally recommended).

Hypertension.

Potential for delayed wound healing (may require holding 3–4 days prior to surgery).

Less frequent toxicities include bleeding, fever, and hand-foot syndrome.[30] Therapy with sunitinib may be cardiotoxic. In a retrospective phase I/II study evaluating the efficacy of sunitinib in patients with imatinib-resistant metastatic GISTs, 8% of patients who received repeated cycles of sunitinib experienced congestive heart failure, while 47% of patients developed hypertension (>150 per 100 mm Hg). Reductions in left ventricular ejection fraction were seen in at least 10% to 28% of patients.[38]

Sources: 30 · 38

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / TKI therapy for imatinib-resistant GISTs

Regorafenib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

The FDA has approved regorafenib for the treatment of GISTs that are refractory to first-line therapy. Regorafenib is a multikinase inhibitor with activity against KIT, PDGFRA, and VEGFR, among others. Regorafenib has demonstrated anti-GIST activity in phase II and phase III studies.[39,40]

Sources: 39 · 40

Evidence (regorafenib):

The phase III double-blind GRID trial (NCT01271712) included 199 patients with advanced GISTs who did not respond to previous imatinib and sunitinib therapy. Patients were randomly assigned in a 2:1 ratio to receive either 160 mg daily of regorafenib (3-weeks-on/1-week-off regimen) (n = 133) or placebo (n = 66). Crossover to open-label regorafenib was allowed for patients who had disease progression on the placebo arm.[40]

Sources: GRID · 40

The phase III double-blind GRID trial (NCT01271712) included 199 patients with advanced GISTs who did not respond to previous imatinib and sunitinib therapy. Patients were randomly assigned in a 2:1 ratio to receive either 160 mg daily of regorafenib (3-weeks-on/1-week-off regimen) (n = 133) or placebo (n = 66). Crossover to open-label regorafenib was allowed for patients who had disease progression on the placebo arm.[40]

After a median treatment duration of 23 weeks for regorafenib and 7 weeks for placebo, the median PFS was longer in patients who received regorafenib (4.8 months) compared with patients who received placebo (0.9 months) (HR, 0.27; 95% CI, 0.19–0.39; P < .0001).[40][Level of evidence B1] The OS did not differ between arms (HR, 0.77; 0.4–1.41; P = .199). However, 56 patients in the placebo arm (85%) did cross over to receive regorafenib at the time of disease progression.

Sources: 40 · Level of evidence B1

Adverse events were more common in the regorafenib arm (98.5%) compared with the placebo arm (68.2%). The most common grade 3 or greater events were hypertension (23.5%), hand-foot syndrome (19.7%), and diarrhea (5.3%).

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

Additional TKI therapy options

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Additional TKI therapy options

Ripretinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Ripretinib is indicated for patients with advanced GISTs who have disease progression on (or are intolerant to) three or more TKIs, including imatinib. It works as a switch control inhibitor with multiple targets, including KIT exons 9, 11, 13, 14, 18, and it stabilizes the KIT molecule in its active form.

Based on the toxicity profile of ripretinib, a baseline echocardiogram or multigated acquisition (MUGA) scan should be obtained, and blood pressure and clinical signs of heart failure should be serially monitored. Dermatologic exams are warranted, given the association with the development of cutaneous cancers and hand-foot syndrome. Ripretinib is teratogenic and warrants concomitant effective contraception. It should also not be given perioperatively (1 week before or 2 weeks after surgery) because of the risk of delayed wound healing.[41,42]

Sources: 41 · 42

Evidence (ripretinib):

INVICTUS (NCT03353753) was a phase III, double-blind, placebo-controlled trial of 129 patients with advanced GISTs who had not responded to previous imatinib, sunitinib, and regorafenib therapy. Patients were randomly assigned in a 2:1 ratio to receive either ripretinib 150 mg daily (n = 85) or placebo (n = 44), with an opportunity to cross over at the time of disease progression.[41]

Sources: INVICTUS · 41

INVICTUS (NCT03353753) was a phase III, double-blind, placebo-controlled trial of 129 patients with advanced GISTs who had not responded to previous imatinib, sunitinib, and regorafenib therapy. Patients were randomly assigned in a 2:1 ratio to receive either ripretinib 150 mg daily (n = 85) or placebo (n = 44), with an opportunity to cross over at the time of disease progression.[41]

After a median follow-up of 6.3 months for the ripretinib arm and 1.6 months for the placebo arm, the median OS was longer for patients who received ripretinib (15.1 months), compared with patients who received placebo (6.6 months) (HR, 0.36; 95% CI, 0.21–0.62).[41][Level of evidence A1]

Sources: 41 · Level of evidence A1

The median PFS was longer for patients who received ripretinib (6.3 months) than patients for who received placebo (1.0 month) (HR, 0.15; 95% CI, 0.09–0.25; P < .0001). The PFS rate at 6 months was 51% in the ripretinib arm (95% CI, 39.4%–61.4%) and 3.2% in the placebo arm (95% CI, 0.2%–13.8%).[41]

Sources: 41

Twenty-nine patients (66%) in the placebo arm crossed over to the ripretinib arm.

Ripretinib was well tolerated. The most common grade 3 or 4 adverse events were lipase increase (5%), hypertension (4%), fatigue (2%), and hypophosphatemia (2%).

INTRIGUE (NCT03673501) was an open-label phase III trial of 453 patients with advanced GISTs who did not respond to imatinib therapy. Patients were randomly assigned to receive either ripretinib 150 mg daily (n = 226) or sunitinib 50 mg (4-weeks-on/2-weeks-off regimen; n = 227).[43]

Sources: INTRIGUE · 43

INTRIGUE (NCT03673501) was an open-label phase III trial of 453 patients with advanced GISTs who did not respond to imatinib therapy. Patients were randomly assigned to receive either ripretinib 150 mg daily (n = 226) or sunitinib 50 mg (4-weeks-on/2-weeks-off regimen; n = 227).[43]

The median PFS did not differ between the ripretinib and sunitinib arms (8.0 months vs. 8.3 months; HR, 1.05; 95% CI, 0.82–1.33; P = .72). In addition, there was no difference in the median PFS in the KIT exon 11 cohort (8.3 months vs. 7.0 months; HR, 0.88; 95% CI, 0.66–1.16; P = .36).[43][Level of evidence B1]

Sources: 43 · Level of evidence B1

OS data were immature at the time of report.

Patients who received ripretinib had fewer treatment-emergent adverse events (41.3% vs. 65.6%; P < .0001) and were more likely to develop drug-related grade 3 or 4 hypertension (5.8% vs. 22.6%). Dose modifications, interruptions, or discontinuations were all less common with ripretinib.

Ripretinib did not lead to a PFS or OS benefit when compared with sunitinib. Therefore, it is not indicated unless the patient's tumor does not respond to prior lines of TKI therapy.

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Additional TKI therapy options

Nilotinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Nilotinib is a second-generation TKI with similar targets to imatinib. A phase III study of nilotinib versus best supportive care in imatinib- and sunitinib-resistant GISTs showed some PFS benefit based on local assessment but no PFS benefit based on central assessment. Post-hoc analysis did reveal a modest but significant median OS difference of 4 months.[44]

Sources: 44

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Additional TKI therapy options

Sorafenib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Sorafenib is a multitarget kinase that is similar in structure and mechanism to regorafenib. A phase II trial of patients with imatinib- and sunitinib-resistant GISTs showed that sorafenib offered potential benefit, with a disease control rate of 68% and a median PFS of 5 months.[45]

Sources: 45

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Additional TKI therapy options

Pazopanib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Pazopanib inhibits VEGF signaling and showed modest PFS benefit when compared to best supportive care in a small phase II trial of patients with imatinib- and sunitinib-resistant GISTs. However, pazopanib had a high rate of toxicity.[46]

Sources: 46

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

TKI therapy for KIT/PDGFRA wild-type GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Patients without KIT or PDGFRA variants, such as SDH-deficient and NF1-related GISTs, do not benefit from initial TKI treatment with imatinib. However, these patients may have modest response to sunitinib and regorafenib.[47] These tumors tend to have a relatively indolent course, and optimal management of these patients remains unknown. Thus, patients should be encouraged to enroll in a clinical trial, if available.

Sources: 47

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

Surgery

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Surgery may be added to medical therapy for selected patients with GISTs in an effort to delay or prevent recurrence, although the benefit of this therapeutic approach in patients with metastatic GISTs has yet to be proven in a randomized clinical trial.

Evidence (surgery):

A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]

Sources: 48 · C2 · C1

A retrospective study involving 69 consecutive patients who underwent surgery for unresectable primary or metastatic GISTs while receiving kinase inhibitors reported the following:[48][Levels of evidence C2 and C1]

Patients with stable disease or limited progression were found to have prolonged survival after debulking procedures. In this group of patients with GISTs, no evidence of disease was found after surgery in 78% of patients with stable disease, 25% of patients with limited progression, and 7% of patients with generalized progression.

The 12-month PFS rate was 80% for patients with stable disease, 33% for patients with limited progression, and 0% for patients with generalized progression.

The 12-month OS rate was 95% for patients with stable disease, 86% for patients with limited progression, and 0% for patients with generalized progression.

The authors of this study concluded that surgery for patients with generalized progression should be limited to a palliative role.

Overall, the indications for surgery in the management of metastatic or recurrent GISTs include:[3]

Sources: 3

Stable disease (i.e., disease that is stable or shrinking on TKI therapy when gross resection is possible).

Limited disease progression (i.e., isolated tumor deposits that are progressing on TKI therapy after initial response [indicating delayed drug resistance], while other sites of disease remain stable).

Oncological emergencies including hemorrhage, perforation, obstruction, or abscess.

Stable disease and limited disease progression identify subsets of patients with advanced disease that are selected for relative disease stability. Therefore, the favorable outcomes that have been noted in case series may be principally the result of selection bias rather than true benefit from surgery.

The median time to the development of secondary resistance to imatinib has been about 2 years.[12] Therefore, it is suggested that surgery for metastatic or recurrent disease in patients receiving imatinib/sunitinib be performed before 2 years. Most experts would recommend considering surgery after 6 to 12 months of disease stability with TKI therapy.[3] Drug therapy may be continued after surgery.

Sources: 12 · 3

Health professional · Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs

Clinical trials

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Patients who have generalized disease progression while receiving standard therapies, or with certain molecular subtypes (i.e., SDH-deficient or NF1-related GISTs) may benefit from enrolling in clinical trials. These patients should be referred to specialized multidisciplinary research centers.

Health professional

Treatment of Resistant or Refractory GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Eventual development of resistance to imatinib, sunitinib, and regorafenib is nearly universal. There is no standard therapy when this occurs, and patients should consider investigational therapy, such as new oral tyrosine kinase inhibitors. If eligible, patients are encouraged to participate in clinical trials.

Health professional

Key References for Treatment of GISTs

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

These references have been identified by members of the PDQ Adult Treatment Editorial Board as significant in the field of gastrointestinal stromal tumor (GIST) treatment. This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for GISTs. Listed after each reference are the sections within this summary where the reference is cited.

Health professional · Key References for Treatment of GISTs

Preoperative Imatinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

8 to 12 weeks

Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99 (1): 42-7, 2009. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99 (1): 42-7, 2009. [PUBMED Abstract]Cited in:

Treatment of Unresectable Primary GISTs

Sources: Treatment of Unresectable Primary GISTs

6 to 9 months

Kurokawa Y, Yang HK, Cho H, et al.: Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117 (1): 25-32, 2017. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Kurokawa Y, Yang HK, Cho H, et al.: Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117 (1): 25-32, 2017. [PUBMED Abstract]Cited in:

Treatment of Unresectable Primary GISTs

Sources: Treatment of Unresectable Primary GISTs

Health professional · Key References for Treatment of GISTs

Postoperative Imatinib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

1 year of imatinib

Dematteo RP, Ballman KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (9669): 1097-104, 2009. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Dematteo RP, Ballman KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (9669): 1097-104, 2009. [PUBMED Abstract]Cited in:

Treatment of Resectable Primary GISTs

Sources: Treatment of Resectable Primary GISTs

2 years of imatinib

Joensuu H, Eriksson M, Sundby Hall K, et al.: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307 (12): 1265-72, 2012. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Joensuu H, Eriksson M, Sundby Hall K, et al.: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307 (12): 1265-72, 2012. [PUBMED Abstract]Cited in:

Treatment of Resectable Primary GISTs

Sources: Treatment of Resectable Primary GISTs

1 year versus 3 years of imatinib

Casali PG, Le Cesne A, Poveda Velasco A, et al.: Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33 (36): 4276-83, 2015. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Casali PG, Le Cesne A, Poveda Velasco A, et al.: Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33 (36): 4276-83, 2015. [PUBMED Abstract]Cited in:

Treatment of Resectable Primary GISTs

Sources: Treatment of Resectable Primary GISTs

5 years of imatinib

Raut CP, Espat NJ, Maki RG, et al.: Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol 4 (12): e184060, 2018. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Raut CP, Espat NJ, Maki RG, et al.: Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol 4 (12): e184060, 2018. [PUBMED Abstract]Cited in:

Treatment of Resectable Primary GISTs

Sources: Treatment of Resectable Primary GISTs

Varying duration of imatinib

Lin JX, Chen QF, Zheng CH, et al.: Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. J Cancer Res Clin Oncol 143 (4): 727-734, 2017. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Lin JX, Chen QF, Zheng CH, et al.: Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. J Cancer Res Clin Oncol 143 (4): 727-734, 2017. [PUBMED Abstract]Cited in:

Treatment of Resectable Primary GISTs

Sources: Treatment of Resectable Primary GISTs

Health professional · Key References for Treatment of GISTs

Advanced GIST Tyrosine Kinase Inhibitors

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024. Captured 2026-09-09.

Imatinib

Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (7): 472-80, 2002. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (7): 472-80, 2002. [PUBMED Abstract]Cited in:

Treatment Option Overview for GISTs

Sources: Treatment Option Overview for GISTs

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 (4): 626-32, 2008. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 (4): 626-32, 2008. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Avapritinib

Heinrich MC, Jones RL, von Mehren M, et al.: Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21 (7): 935-946, 2020. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Heinrich MC, Jones RL, von Mehren M, et al.: Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21 (7): 935-946, 2020. [PUBMED Abstract]Cited in:

Treatment Option Overview for GISTs

Sources: Treatment Option Overview for GISTs

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Avapritinib versus regorafenib

Kang YK, George S, Jones RL, et al.: Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol 39 (28): 3128-3139, 2021. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Kang YK, George S, Jones RL, et al.: Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol 39 (28): 3128-3139, 2021. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Sunitinib

Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (9544): 1329-38, 2006. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (9544): 1329-38, 2006. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Regorafenib

Demetri GD, Reichardt P, Kang YK, et al.: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (9863): 295-302, 2013. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Demetri GD, Reichardt P, Kang YK, et al.: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (9863): 295-302, 2013. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Ripretinib

Blay JY, Serrano C, Heinrich MC, et al.: Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21 (7): 923-934, 2020. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Blay JY, Serrano C, Heinrich MC, et al.: Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21 (7): 923-934, 2020. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

Ripretinib versus sunitinib

Bauer S, Jones RL, Blay JY, et al.: Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 40 (34): 3918-3928, 2022. [PUBMED Abstract]Cited in:

Sources: PUBMED Abstract

Bauer S, Jones RL, Blay JY, et al.: Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 40 (34): 3918-3928, 2022. [PUBMED Abstract]Cited in:

Treatment of Metastatic or Recurrent GISTs

Sources: Treatment of Metastatic or Recurrent GISTs

For patients · General Information About Gastrointestinal Stromal Tumors

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

The prognosis and treatment options depend on the following:

Sources: prognosis

How quickly the cancer cells are growing and dividing.

The size of the tumor.

Where the tumor is in the body.

Whether the tumor can be completely removed by surgery.

Whether the tumor has spread to other parts of the body.

For patients · Stages of Gastrointestinal Stromal Tumors

The results of diagnostic and staging tests are used to plan treatment.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For many cancers it is important to know the stage of the cancer in order to plan treatment. However, the treatment of GIST is not based on the stage of the cancer. Treatment is based on whether the tumor can be removed by surgery and if the tumor has spread to other parts of the abdomen or to distant parts of the body.

Sources: GIST · surgery · abdomen

Treatment is based on whether the tumor is:

Resectable: These tumors can be removed by surgery .

Sources: Resectable

Unresectable: These tumors cannot be completely removed by surgery.

Sources: Unresectable

Metastatic and recurrent: Metastatic tumors have spread to other parts of the body. Recurrent tumors have recurred (come back) after treatment. Recurrent GISTs may come back in the gastrointestinal tract or in other parts of the body. They are usually found in the abdomen, peritoneum, and/or liver.

Sources: Metastatic · recurrent · recurred · peritoneum · liver

Refractory: These tumors have not gotten better with treatment.

Sources: Refractory

For patients

Treatment Option Overview

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

There are different types of treatment for patients with gastrointestinal stromal tumors.

Four types of standard treatment are used:

Four types of standard treatment are used:

Surgery

Targeted therapy

Watchful waiting

Supportive care

New types of treatment are being tested in clinical trials.

Treatment for gastrointestinal stromal tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with gastrointestinal stromal tumors.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

Different types of treatments are available for patients with gastrointestinal stromal tumors (GISTs). Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: gastrointestinal stromal tumors · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

Four types of standard treatment are used:

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For patients · Treatment Option Overview / Four types of standard treatment are used:

Surgery

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

If the GIST has not spread and is in a place where surgery can be safely done, the tumor and some of the tissue around it may be removed. Sometimes surgery is done using a laparoscope (a thin, lighted tube) to see inside the body. Small incisions (cuts) are made in the wall of the abdomen and a laparoscope is inserted into one of the incisions. Instruments may be inserted through the same incision or through other incisions to remove organs or tissues.

Sources: surgery · tumor · tissue · laparoscope · incisions · abdomen · organs

For patients · Treatment Option Overview / Four types of standard treatment are used:

Targeted therapy

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.

Sources: Targeted therapy · drugs · cells · chemotherapy · radiation therapy

Tyrosine kinase inhibitors (TKIs) are targeted therapy drugs that block signals needed for tumors to grow. TKIs may be used to treat GISTs that cannot be removed by surgery or to shrink GISTs so they become small enough to be removed by surgery. Imatinib mesylate and sunitinib are two TKIs used to treat GISTs. TKIs are sometimes given for as long as the tumor does not grow and serious side effects do not occur.

Sources: Tyrosine kinase inhibitors · Imatinib mesylate · sunitinib · side effects

See Drugs Approved for Gastrointestinal Stromal Tumors for more information.

Sources: Drugs Approved for Gastrointestinal Stromal Tumors

For patients · Treatment Option Overview / Four types of standard treatment are used:

Watchful waiting

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.

Sources: Watchful waiting · monitoring · condition · signs · symptoms

For patients · Treatment Option Overview / Four types of standard treatment are used:

Supportive care

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

If a GIST gets worse during treatment or there are side effects, supportive care is usually given. The goal of supportive care is to prevent or treat the symptoms of a disease, side effects caused by treatment, and psychological, social, and spiritual problems related to a disease or its treatment. Supportive care helps improve the quality of life of patients who have a serious or life-threatening disease. Radiation therapy is sometimes given as supportive care to relieve pain in patients with large tumors that have spread.

Sources: supportive care · psychological · spiritual · quality of life · Radiation therapy

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for gastrointestinal stromal tumors may cause side effects.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

Follow-up for GISTs that were removed by surgery may include CT scan of the liver and pelvis or watchful waiting. For GISTs that are treated with tyrosine kinase inhibitors, follow-up tests, such as CT, MRI, or PET scans, may be done to check how well the targeted therapy is working.

Sources: CT scan · liver · pelvis · MRI · PET scans

For patients

Treatment of Resectable Gastrointestinal Stromal Tumors

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Resectable gastrointestinal stromal tumors (GISTs) can be completely or almost completely removed by surgery. Treatment may include the following:

Sources: Resectable · gastrointestinal stromal tumors · surgery

Surgery to remove tumors that are 2 centimeters or larger. Laparoscopic surgery may be done if the tumor is 5 cm or smaller. If there are cancer cells remaining at the edges of the area where the tumor was removed, watchful waiting or targeted therapy with imatinib mesylate may follow.

Sources: tumors · centimeters · Laparoscopic surgery · cancer · cells · watchful waiting · targeted therapy · imatinib mesylate

A clinical trial of targeted therapy with imatinib mesylate following surgery, to decrease the chance the tumor will recur (come back).

Sources: clinical trial · recur

For patients

Treatment of Unresectable Gastrointestinal Stromal Tumors

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Unresectable GISTs cannot be completely removed by surgery because they are too large or in a place where there would be too much damage to nearby organs if the tumor is removed. Treatment is usually a clinical trial of targeted therapy with imatinib mesylate to shrink the tumor, followed by surgery to remove as much of the tumor as possible.

Sources: Unresectable · GISTs · surgery · organs · tumor · clinical trial · targeted therapy · imatinib mesylate

For patients

Treatment of Metastatic and Recurrent Gastrointestinal Stromal Tumors

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of GISTs that are metastatic (spread to other parts of the body) or recurrent (came back after treatment) may include the following:

Sources: GISTs · metastatic · recurrent

Targeted therapy with imatinib mesylate.

Sources: Targeted therapy · imatinib mesylate

Targeted therapy with sunitinib, if the tumor begins to grow during imatinib mesylate therapy or if the side effects are too bad.

Sources: sunitinib · tumor · side effects

Surgery to remove tumors that have been treated with targeted therapy and are shrinking, stable (not changing), or that have slightly increased in size. Targeted therapy may continue after surgery.

Sources: Surgery · stable

Surgery to remove tumors when there are serious complications, such as bleeding, a hole in the gastrointestinal (GI) tract, a blocked GI tract, or infection.

Sources: complications · gastrointestinal (GI) tract · infection

A clinical trial of a new treatment.

Sources: clinical trial

For patients

Treatment of Refractory Gastrointestinal Stromal Tumors

Source: Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 28, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Many GISTs treated with a tyrosine kinase inhibitor (TKI) become refractory (stop responding) to the drug after a while. Treatment is usually a clinical trial with a different TKI or a clinical trial of a new drug.

Sources: GISTs · tyrosine kinase inhibitor · refractory · drug · clinical trial

Studies

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

NCT00028002 · COMPLETED · phase2

Gastrointestinal Stromal Tumor

ClinicalTrials.gov record

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

NCT00041197 · COMPLETED · phase3

Gastrointestinal Stromal Tumor

ClinicalTrials.gov record

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

NCT00103168 · COMPLETED · phase3

Gastrointestinal Stromal Tumor

ClinicalTrials.gov record

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

NCT00116935 · COMPLETED · phase3

Sarcoma

ClinicalTrials.gov record

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

NCT00867113 · COMPLETED · phase2

Gastrointestinal Stromal Tumor (GIST)

ClinicalTrials.gov record

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

NCT01271712 · COMPLETED · phase3

Gastrointestinal Stromal Tumors

ClinicalTrials.gov record

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

NCT02508532 · COMPLETED · phase1

Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors

ClinicalTrials.gov record

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

NCT03353753 · COMPLETED · phase3

Gastrointestinal Stromal Tumors

ClinicalTrials.gov record

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03465722 · COMPLETED · phase3

GIST

ClinicalTrials.gov record

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501 · ACTIVE NOT RECRUITING · phase3

Gastrointestinal Stromal Tumors

ClinicalTrials.gov record

Disease and treatment settings

advanced Gastrointestinal Stromal Tumors

Disease and treatment setting

Advanced GIST Tyrosine Kinase Inhibitors

Ayvakit: unresectable metastatic gastrointestinal stromal tumor with PDGFRA Exon 18, PDGFRA stated without a specific alteration

Disease and treatment setting

1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor...

Ayvakit: unresectable metastatic gastrointestinal stromal tumor with PDGFRA stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA)...

Gastrointestinal Stromal Tumors

Disease and treatment setting

Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Disease and treatment setting

Treatment of Resectable Primary GISTs

Gastrointestinal Stromal Tumors

Disease and treatment setting

Treatment of Unresectable Primary GISTs

Gleevec: Gastrointestinal Stromal Tumors with KIT stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)

QINLOCK: advanced gastrointestinal stromal tumor after prior therapy

Disease and treatment setting

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

recurrent Gastrointestinal Stromal Tumors

Disease and treatment setting

Treatment of Metastatic or Recurrent GISTs

refractory Gastrointestinal Stromal Tumors

Disease and treatment setting

Treatment of Resistant or Refractory GISTs

Stivarga: unresectable metastatic Gastrointestinal Stromal Tumors

Disease and treatment setting

1.2 Gastrointestinal Stromal Tumors STIVARGA is indicated for the treatment of adult patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib...

SUTENT: gastrointestinal stromal tumor after prior therapy

Disease and treatment setting

• treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.

Drug labels

Ayvakit

Label date 2026-08-05

AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation,...

DailyMed label

QINLOCK

Label date 2025-05-12

QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated...

DailyMed label

Stivarga

Label date 2026-02-09

STIVARGA is a kinase inhibitor indicated for the treatment of adult patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an...

DailyMed label